KR102532559B1 - 형질감염을 개선하는 막 투과 펩타이드 및 조성물 그리고 이들을 사용하는 방법 - Google Patents

형질감염을 개선하는 막 투과 펩타이드 및 조성물 그리고 이들을 사용하는 방법 Download PDF

Info

Publication number
KR102532559B1
KR102532559B1 KR1020167018604A KR20167018604A KR102532559B1 KR 102532559 B1 KR102532559 B1 KR 102532559B1 KR 1020167018604 A KR1020167018604 A KR 1020167018604A KR 20167018604 A KR20167018604 A KR 20167018604A KR 102532559 B1 KR102532559 B1 KR 102532559B1
Authority
KR
South Korea
Prior art keywords
peptide
transfection
cells
arg arg
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167018604A
Other languages
English (en)
Korean (ko)
Other versions
KR20160103024A (ko
Inventor
자비에 드 몰르라 뒤 쥬
Original Assignee
라이프 테크놀로지스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라이프 테크놀로지스 코포레이션 filed Critical 라이프 테크놀로지스 코포레이션
Publication of KR20160103024A publication Critical patent/KR20160103024A/ko
Application granted granted Critical
Publication of KR102532559B1 publication Critical patent/KR102532559B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020167018604A 2013-12-12 2014-12-12 형질감염을 개선하는 막 투과 펩타이드 및 조성물 그리고 이들을 사용하는 방법 Active KR102532559B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915429P 2013-12-12 2013-12-12
US61/915,429 2013-12-12
PCT/US2014/070176 WO2015089487A1 (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Publications (2)

Publication Number Publication Date
KR20160103024A KR20160103024A (ko) 2016-08-31
KR102532559B1 true KR102532559B1 (ko) 2023-05-16

Family

ID=52273587

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167018604A Active KR102532559B1 (ko) 2013-12-12 2014-12-12 형질감염을 개선하는 막 투과 펩타이드 및 조성물 그리고 이들을 사용하는 방법

Country Status (11)

Country Link
US (5) US9856496B2 (https=)
EP (2) EP3756690A3 (https=)
JP (2) JP6912887B2 (https=)
KR (1) KR102532559B1 (https=)
CN (2) CN113105559A (https=)
AU (2) AU2014361806B2 (https=)
BR (1) BR112016013516A8 (https=)
CA (1) CA2933561A1 (https=)
ES (1) ES2808866T3 (https=)
SG (2) SG10201811729PA (https=)
WO (1) WO2015089487A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6473079B2 (ja) * 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
CN104583957B (zh) 2012-06-15 2018-08-10 英特尔公司 具有无消歧乱序加载存储队列的重新排序的推测性指令序列
EP2862062B1 (en) 2012-06-15 2024-03-06 Intel Corporation A virtual load store queue having a dynamic dispatch window with a distributed structure
CN107748673B (zh) 2012-06-15 2022-03-25 英特尔公司 包括虚拟加载存储队列的处理器和系统
CN104823168B (zh) 2012-06-15 2018-11-09 英特尔公司 用于实现从由加载存储重新排序和优化导致的推测性转发遗漏预测/错误中恢复的方法和系统
TWI646422B (zh) 2012-06-15 2019-01-01 英特爾股份有限公司 在處理器中之免消歧義失序載入／儲存佇列方法、微處理器、和非暫態性電腦可讀取儲存媒體
EP2862069A4 (en) 2012-06-15 2016-12-28 Soft Machines Inc INSTRUCTION DEFINITION FOR IMPLEMENTING LOAD MEMORY TRANSFER AND OPTIMIZATION
BR112016013516A8 (pt) 2013-12-12 2020-05-19 Life Technologies Corp complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
KR102669726B1 (ko) 2015-07-13 2024-05-29 라이프 테크놀로지스 코포레이션 Cho 세포에서의 개선된 일시적 단백질 발현을 위한 시스템 및 방법
EP3423438A4 (en) * 2016-03-01 2020-05-06 Molecular Transfer, Inc. PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
JP7216641B2 (ja) * 2016-09-30 2023-02-01 ライフ テクノロジーズ コーポレイション レンチウイルス製造用無血清懸濁系
LT3675826T (lt) 2017-08-31 2023-09-11 Life Technologies Corporation Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui
EP3684797A4 (en) 2017-09-19 2021-07-07 Cannametrix, LLC CELL BASED ASSAY FOR QUANTIFYING THE POWER AND EFFECTIVENESS OF CANNABINOIDS AND / OR TERPENOIDS, AND RELATED METHODS OF USE
EP3765030A4 (en) * 2018-03-16 2022-01-26 Sarepta Therapeutics, Inc. CHIMERIC PEPTIDES FOR ANTISENSE ADMINISTRATION
EP3833745A1 (en) 2018-08-10 2021-06-16 REGENXBIO Inc. Scalable method for recombinant aav production
WO2020077178A1 (en) * 2018-10-12 2020-04-16 Ann & Robert H. Lurie Children's Hospital of Chicago Plga-peg/pei nanoparticles and methods of use
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
CA3130108A1 (en) * 2019-02-22 2020-08-27 Life Technologies Corporation Suspension system for adeno associated virus production
EP4005583A4 (en) * 2019-04-01 2023-04-26 Industry - University Cooperation Foundation Hanyang University ANTI-CANCER AGAINST PEPTIDE-BASED CP2C
KR102261371B1 (ko) * 2019-04-01 2021-06-08 한양대학교 산학협력단 CP2c 표적 펩티드 기반 항암제
KR20220046605A (ko) * 2019-08-05 2022-04-14 뽈리쁠뤼스-트랑스펙씨옹 (쏘시에떼 아노님) 양이온성 중합체에 그래프트된 헤테로사이클릭 화합물을 포함하는, 세포 내로 핵산 분자를 형질감염시키기 위한 조성물, 및 이의 적용
KR102515464B1 (ko) * 2020-04-29 2023-03-28 연세대학교 원주산학협력단 핵산 또는 유전자 형질감염 효율을 개선하는 세포독성 완화 막 투과 펩타이드 및 이의 용도
US20260027179A1 (en) * 2021-02-08 2026-01-29 University Of British Columbia Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases
CN118475355A (zh) 2021-07-08 2024-08-09 日本新药株式会社 肾毒性减轻剂
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
CA3225573A1 (en) 2021-07-08 2023-01-12 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent
CN113563429A (zh) * 2021-07-19 2021-10-29 天津大学 一种基于烷基化多肽的核酸递送系统及制备方法与应用
WO2023014909A1 (en) * 2021-08-04 2023-02-09 AJK Biopharmaceutical, LLC Amphiphilic peptides for nucleic acid and protein delivery
CN114106095B (zh) * 2021-11-11 2023-06-09 华南理工大学 基于聚集诱导发光原理的细胞自噬检测分子探针及其制备方法和应用
WO2023171804A1 (ja) 2022-03-10 2023-09-14 日本新薬株式会社 抗ウイルスアンチセンスオリゴマー
KR102717793B1 (ko) * 2022-05-26 2024-10-16 주식회사 바이오셀트란 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물
CN119604312A (zh) 2022-06-30 2025-03-11 生命技术公司 用于体内递送的脂质组合物
GB202211597D0 (en) 2022-08-09 2022-09-21 Nchain Licensing Ag Computer-implemented method and system
EP4642434A2 (en) 2022-12-29 2025-11-05 Life Technologies Corporation Lipid compositions on the basis of ionizable lipids, use for delivery to immune cells
CN115947817B (zh) * 2023-02-22 2024-07-02 甘肃中肽生物科技有限公司 一种肿瘤相关多肽及其制备方法和应用
WO2026036019A1 (en) 2024-08-09 2026-02-12 Life Technologies Corporation Method of producing a recombinant protein in hek-293 cells
WO2026076376A1 (en) 2024-10-06 2026-04-09 Mirus Bio Llc Transfection reagent comprising cationic polymer and amphipathic compound
CN119775363A (zh) * 2024-12-31 2025-04-08 澳门科技大学 一种多肽、免疫原、疫苗和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040502A1 (en) * 1997-03-14 1998-09-17 Life Technologies, Inc. Peptide-enhanced transfections
WO2002072616A2 (en) * 2001-03-14 2002-09-19 Ich Productions Limited Transfection complexes
WO2013138795A1 (en) 2012-03-15 2013-09-19 Permeon Biologics, Inc. Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5316948A (en) 1992-09-04 1994-05-31 Life Technologies, Inc. N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
JP5610659B2 (ja) 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
CA2513072A1 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
WO2004105697A2 (en) 2003-05-22 2004-12-09 Molecular Transfer, Inc. Novel lipids for transfection of nucleic acids
DE602004022056D1 (de) * 2003-08-14 2009-08-27 Diatos Antibakterielle zusammensetzung, vor allem zur bekämpfung gramnegativer bakterien, umfassend ein peptid und ein vorteilhafterweise hydrophobes antibakterielles agens
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
ATE501169T1 (de) * 2005-12-30 2011-03-15 Evonik Roehm Gmbh Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
AU2007232206B2 (en) 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
NZ593080A (en) 2006-05-05 2012-12-21 Molecular Transfer Inc Novel reagents for transfection of eukaryotic cells
JP5403681B2 (ja) 2007-03-07 2014-01-29 独立行政法人国立国際医療研究センター 新規核内移行ペプチド
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011127210A1 (en) 2010-04-06 2011-10-13 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
CN103097397B (zh) * 2010-05-30 2015-11-25 多伦多大学管理委员会 作为抗癌化合物载体的线粒体穿透肽
RU2556800C2 (ru) 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CN103380113B (zh) 2010-11-15 2018-03-30 生命科技公司 含胺的转染试剂及其制备和使用方法
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
US8853145B2 (en) * 2011-11-14 2014-10-07 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins
BR112016013516A8 (pt) 2013-12-12 2020-05-19 Life Technologies Corp complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula
KR102476764B1 (ko) * 2015-12-23 2022-12-14 에스케이하이닉스 주식회사 소자분리구조 및 그 제조 방법
US9926825B2 (en) 2016-04-19 2018-03-27 GM Global Technology Operations LLC Method and apparatus for exhaust purification for an internal combustion engine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040502A1 (en) * 1997-03-14 1998-09-17 Life Technologies, Inc. Peptide-enhanced transfections
WO2002072616A2 (en) * 2001-03-14 2002-09-19 Ich Productions Limited Transfection complexes
WO2013138795A1 (en) 2012-03-15 2013-09-19 Permeon Biologics, Inc. Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Also Published As

Publication number Publication date
JP2020015747A (ja) 2020-01-30
JP6985347B2 (ja) 2021-12-22
KR20160103024A (ko) 2016-08-31
EP3079723B1 (en) 2020-05-27
BR112016013516A8 (pt) 2020-05-19
AU2014361806B2 (en) 2019-12-19
WO2015089487A1 (en) 2015-06-18
SG10201811729PA (en) 2019-02-27
US20150211021A1 (en) 2015-07-30
BR112016013516A2 (https=) 2017-08-08
CA2933561A1 (en) 2015-06-18
ES2808866T3 (es) 2021-03-02
EP3756690A2 (en) 2020-12-30
US12152248B2 (en) 2024-11-26
JP2017500856A (ja) 2017-01-12
AU2020202002A1 (en) 2020-04-09
AU2020202002B2 (en) 2021-08-05
EP3756690A3 (en) 2021-03-17
SG11201604697TA (en) 2016-07-28
CN106456793B (zh) 2021-04-30
US20180163231A1 (en) 2018-06-14
CN113105559A (zh) 2021-07-13
US9856496B2 (en) 2018-01-02
AU2014361806A1 (en) 2016-07-28
US20250109412A1 (en) 2025-04-03
EP3079723A1 (en) 2016-10-19
US20200392537A1 (en) 2020-12-17
US10760098B2 (en) 2020-09-01
CN106456793A (zh) 2017-02-22
JP6912887B2 (ja) 2021-08-04
US20250263751A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
US20250263751A1 (en) Membrane-penetrating peptides to enhanced transfection and compositions and methods for using same
Gooding et al. siRNA delivery: from lipids to cell‐penetrating peptides and their mimics
US6376248B1 (en) Peptide-enhanced transfections
JP5683533B2 (ja) 真核細胞のトランスフェクションのための新規試薬
US8759499B2 (en) Lipids for transfection of Eukaryotic cells
US20030144230A1 (en) Peptide-enhanced transfections
JP2023545546A (ja) 遺伝子発現調節のための非アニオン性ポリヌクレオチド類似体のペプチドに基づく導入
AU2012268866B2 (en) Novel reagents for transfection of eukaryotic cells
Nore A synthetic cell-penetrating peptide (CPP) with protamine conjugate utilized for gene delivery

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160711

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191211

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210705

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210705

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220121

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210906

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191211

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220328

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20230217

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220928

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220223

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220121

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210906

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191211

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230510

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230511

End annual number: 3

Start annual number: 1

PG1601 Publication of registration